Eledon Pharmaceuticals, Inc. ELDN
2.41 USD -0.27 (-9.93%)
Nov 12, 2026, 1:52 PM EST
2.41 Day range 2.65
1.35 52-week range 4.49
- YTD
- +59.27%
- 1 year
- +27.25%
Benzinga news
benzinga.com Eledon Pharma Reports Improved Quality Of Life And Reduced Symptom Burden With Tegoprubart In Kidney Transplant Patients At ASN Kidney Week 2026 Tegoprubart-treated patients demonstrated a mean improvement on the total MTSOSD-59R symptom occurrence scale at 12 months while tacrolimus-treated patients experienced a mean worsening of symptom
benzinga.com Eledon Presents Updated Long-Term Data From Phase 2 BESTOW Clinical Program Evaluating Tegoprubart In Patients Undergoing Kidney Transplantation At International Congress Of The Transplantation Society Tegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an approximately 13 mL/min/1.73 m² advantage versus…
benzinga.com Eledon Pharmaceuticals Says FDA Grants Fast Track Designation To Tegoprubart For Prevention Of Rejection In Kidney Transplantation; Expects To Initiate Phase 3 LEGACY Study In Q4 2026 Tegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an approximately 13 mL/min/1.73 m² advantage versus…
benzinga.com Eledon Pharma Q2 EPS $(0.27) Misses $(0.16) Estimate Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.16) by 68.75 percent. This is a 107.69 percent decrease over losses of…
benzinga.com This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday Wall Street analysts upgraded Fortinet, Goldman Sachs, Adaptive Biotechnologies, and Five Below, with positive outlooks and raised price targets.
benzinga.com This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Top Wall Street analysts change outlook on top stocks. For analyst rating changes, see https://www.benzinga.com/analyst-stock-ratings. INSM initiated with $192 PT.
benzinga.com Rodman & Renshaw Initiates Coverage On Eledon Pharmaceuticals with Buy Rating, Announces Price Target of $12 Rodman & Renshaw analyst Seema Sheoran initiates coverage on Eledon Pharmaceuticals (NASDAQ:ELDN) with a Buy rating and announces Price Target of $12.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Q32 Bio (NASDAQ:QTTB) stock moved upwards by 44.4% to $16.19 during Friday's after-market session. The company's market cap stands at $213.4 million. China Pharma Holding (AMEX:CPHI) shares…- benzinga.com NewcelX Completes Type B Pre-IND Meeting With FDA; Administration Provided Constructive Feedback And Alignment On Proposed Strategy The FDA provided clarity regarding the regulatory pathway toward launching a clinical trial of NCEL-101 for type 1 diabetes in combination with Eledon Pharmaceuticals’ (NASDAQ:ELDN) anti-CD40L…
- benzinga.com Natera Partners With Eledon Pharmaceuticals To Incorporate Its Prospera Kidney Transplant Assessment Test Into Eledon’s Planned Phase 3 Clinical Trial Of Tegoprubart, An Investigational Therapy Designed To Prevent Organ Rejection In Kidney Transplantation Eledon has established the regulatory framework for its Phase 3 kidney transplantation program and plans to initiate the trial in late 2026.Under the agreement, Natera’s Prospera test will serve as…
benzinga.com Eledon Pharma Announces New Long-Term Data From Phase 2 BESTOW Clinical Program Evaluating Tegoprubart In Patients Undergoing Kidney Transplantation, Presented At ATC 2026 Tegoprubart-treated patients maintained higher mean eGFR over time, including a statistically significant approximately 12 mL/min/1.73 m² advantage at month 18 versus tacrolimus (74 vs. 61…- benzinga.com Eledon Pharmaceuticals Announces Updated Results From A Trial Evaluating Tegoprubart, Its Investigational Anti-CD40L Antibody; All 12 Patients Treated In The Study Showed Rapid Improvement In Glycemic Control Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced updated results from an investigator-initiated trial evaluating tegoprubart, its investigational anti-CD40L antibody, as part of…
- benzinga.com Eledon Pharmaceuticals To Present Updated Data From Investigator-Initiated Study At American Diabetes Association 86th Scientific Sessions Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that updated results from an investigator-initiated trial being conducted at the University of Chicago Medicine Transplant…
benzinga.com EXCLUSIVE: NewcelX Advances Diabetes Therapy Toward Human Trials With FDA Pre-IND Submission NewcelX submitted an FDA Pre-IND package for NCEL-101 to advance its type 1 diabetes treatment into human trials.- benzinga.com Eledon Pharma To Highlight New Clinical Data From Tegoprubart Program In Patients Undergoing Kidney Transplantation In Oral And Poster Presentation At ATC 2026 Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the Company will present new clinical data from its tegoprubart program in patients undergoing kidney transplantation in an…
benzinga.com Eledon Pharma Q1 EPS $(0.33) Misses $(0.18) Estimate Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.18) by 83.33 percent. This is a 312.5 percent decrease over losses of…- benzinga.com Eledon Pharmaceuticals Files Prospectus For Offering $500M Securities https://www.sec.gov/Archives/edgar/data/1404281/000119312526201426/d79008ds3.htm
benzinga.com EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug NewcelX reports 2025 results, highlights NCEL-101 progress, $3.4 million financing potential, and plans accelerated execution in 2026.- benzinga.com NewcelX Advances Diabetes Program With New Drug Partnership With Eledon Pharma To Prevent Transplant Rejection NewcelX Ltd. (NASDAQ:NCEL),– NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the release of an updated corporate…
- benzinga.com Eledon Pharma Q4 EPS $(0.10) Beats $(0.18) Estimate Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.18) by 45.95 percent. This is a 84.38 percent increase over losses of…
benzinga.com Eledon Pharmaceuticals Says Investigator-Initiated Islet Transplant Trial Of Tegoprubart For Diabetes Shows 100% Insulin Independence Achieved In 10 Patients Who Are Over 4 Weeks Post-transplant Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced updated results from an investigator-initiated trial conducted at the University of Chicago Medicine Transplant Institute and…- benzinga.com Newcelx Announces Collaborative Research Agreement With Eledon Pharmaceuticals To Advance The NCEL-101 Program For Type 1 Diabetes The collaboration is designed to advance combination strategies integrating NewcelX's lead program, NCEL-101, with Eledon's investigational anti-CD40L monoclonal antibody, tegoprubart (AT-1501), with…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com Eledon Pharma To Present 24-Month Follow-Up Data From Eight Patients Enrolled In Phase 1b Trial Long-Term Extension Evaluating Tegoprubart In Kidney Transplantation At 2026 ASTS Winter Symposium Data from eight participants continue to support safety and tolerability profile of tegoprubartMean eGFR increased over the measurement period, from 67.0 mL/min/1.73 m² at 12 months to 74.2…
benzinga.com Eledon Pharmaceuticals Expects To Present 24-Month Data From 8 Participants In Phase 1 Extension Study Evaluating Tegoprubart In Kidney Transplantation In 2026; Report Other Data From Phase 1, 2 BESTOW Trials Eledon Pharmaceuticals, Inc. ("Eledon") (Nasdaq: ELDN) today announced a summary of 2025 accomplishments and provided guidance for anticipated upcoming 2026 business milestones.- benzinga.com Eledon Pharmaceuticals Data From First Six Participants Of Investigator-Initiated Study Of Anti-CD40 Ligand Demonstrates Marked Improvements In Glycemic Control Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced preliminary results from an investigator-initiated trial conducted at the University of Chicago Medicine's Transplant Institute…
- benzinga.com Guggenheim Maintains Buy on Eledon Pharmaceuticals, Lowers Price Target to $8 Guggenheim analyst Vamil Divan maintains Eledon Pharmaceuticals (NASDAQ:ELDN) with a Buy and lowers the price target from $9 to $8.
- benzinga.com Eledon Pharma Q3 EPS $(0.21) Beats $(0.24) Estimate Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.24) by 11.39 percent. This is a 25 percent increase over losses of $(0.28)…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Eledon Pharmaceuticals Launches ~$50M Offering Of 15.2M Common Shares At $1.65/Share; 15.2M Warrants At $1.649/Warrant Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN), today announced the pricing of its underwritten public offering of (i) 15,152,485 shares of its common stock at a public offering price of…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com Eledon Pharmaceuticals Reveals Proposed Underwritten Public Offering of Common Stock And Pre-Funded Warrants; Size Not Disclosed Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN), today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain…
benzinga.com Eledon Pharmaceuticals' Lead Asset Fails In Mid-Stage Study, But Pushes Forward With Pivotal Study Eledon shares drop as tegoprubart misses the main goal in Phase 2 kidney transplant trial, though safety signals and kidney function data remain encouraging.
benzinga.com Dow Dips Over 200 Points; Fluor Shares Slide After Q3 Results - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Eledon Pharmaceuticals' Phase 2 BESTOW Trial Shows Tegoprubart Maintains Strong Kidney Function And Safety, Supporting Phase 3 Advancement In Transplant Rejection Prevention Data from patients who remained on tegoprubart for a year post transplant showed an overall mean 12-month estimated glomerular filtration rate (eGFR) of approximately 69 mL/min/1.73 m² Tegoprubart…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 56 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 64 companies achieved new lows for the year.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's session, 212 companies made new 52-week lows.
- benzinga.com Earnings Scheduled For May 11, 2023 Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its…
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 220 stocks hit new 52-week lows.
- benzinga.com Earnings Scheduled For March 30, 2023 Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is estimated to report quarterly loss at $0.12 per share on revenue of $10.80 million.